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Abstract The effects of bisphosphonate treatment sche-
dule onfracturehealinghave notpreviouslybeen tested.We
evaluated the effect of ibandronate dosing interval duration
onhealingfollowingsurgical‘‘fracture’’(osteotomy)usinga
rat femoral fracture model. Six-week-old rats (n = 160)
underwent osteotomy and were then allocated into vehicle
control (CNT) or an ibandronate treatment group: 5 lg/kg
daily (DAY, 5 days/week), 75 lg/kg once every 3 weeks
(I-3), 150 lg/kg once every 6 weeks (I-6), resulting in the
same total ibandronate dose over the study. Rats were killed
after 6 or 18 weeks. At 18 weeks, all fracture lines had dis-
appeared in the CNT and I-6 groups; approximately 10% of
fracture lines remained in the DAY and I-3 groups. Ibandr-
onate-treated groups showed large callus areas around the
fractures, which shrank between 6 and 18 weeks after sur-
gery; the extent of shrinkage decreased with shorter dosing
interval. In histomorphometry, callus remodeling was sup-
pressedbyibandronate;thisbecamemoreapparentatshorter
dose intervals. The structural properties of osteotomized
femora were increased in the DAY group compared with
CNT, but intrinsic material properties reduced inversely and
became closer to those of CNT in response to increased
dosing interval. Ibandronate induced formation of large
calluses around osteotomies but delayed woven bone
remodelingintolamellarboneandreducedintrinsicmaterial
properties in a rat fracture model. Extending the dosing
interval of intermittent ibandronate treatment appeared to
reduce the suppression of callus remodeling caused by
ibandronate, which would have delayed healing after
osteotomy.
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Bisphosphonates are strong inhibitors of bone resorption
and are widely used as effective therapeutic agents for a
variety of bone diseases with high bone resorption, such as
metastatic bone disease, Paget disease, and osteoporosis
[1–5]. Currently, they are the most popular therapeutic
agents for osteoporosis because they consistently decrease
the incidence of osteoporotic fragility fractures [6–10].
Nitrogen (N)–containing bisphosphonates may persist on
the bone surface for considerable periods of time, which
has led to the widespread use of intermittent dosing in
clinical practice. For the oral N-containing bisphospho-
nates risedronate and alendronate, this has resulted in a
move from daily to weekly administration of a dose
equivalent to seven times the standard daily dose [11–14].
Ibandronate is an N-containing bisphosphonate that has
beendevelopedspeciﬁcallyforadministrationwithlongdose-
freeintervals[15] and has beenapprovedintheUnitedStates
and Europe as a once-monthly oral regimen. The antifracture
efﬁcacyofibandronatehasbeendemonstratedwithbothdaily
dosingandintermittent treatment,witha dose-freeintervalof
greater than 2 months [16]. In addition, once-monthly
ibandronate has shown therapeutic equivalence to daily
ibandronate for bone mineral density (BMD) gains at the
lumbarspineandthehipwithgoodsafetyandtolerability[17].
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DOI 10.1007/s00223-011-9563-4As fractures may occur in patients undergoing treatment
for osteoporosis, clinicians must be aware of the effects of
therapeutic agents for osteoporosis on the fracture healing
process. We previously reported the effects of antiresorp-
tive agents such as bisphosphonates [18–21], eel calcitonin
(elcatonin) [22], and selective estrogen receptor modulator
(SERM) [21] on fracture healing. These agents delay the
fracture healing process in response to the extent of callus
remodeling suppression, although restoration of the
mechanical strength of fractured bone is not impaired.
Intermittent bisphosphonate dosing regimens are more
common for osteoporosis treatment than daily dosing [13];
however, the effects of the dosing interval on the fracture
healing process have never been tested. We conducted the
current study to evaluate the effects of the dosing interval
of ibandronate on the healing process, especially callus
remodeling, geometrical changes, and mechanical proper-
ties of fractured bone, using a rat femoral fracture model
that imitates fracture development through osteotomy.
Materials and Methods
Materials
Female Sprague-Dawley rats (n = 160) aged 6 weeks were
purchased from Japan SLC (Hamamatsu, Japan) and accli-
mated for 3 weeks to local vivarium conditions (24 ± 2C
and 12-h light–dark cycle). During the experimental period
animals were housed in cages (988 cm
2 in ﬂoor area and
18 cm in height) and allowed free access to water and a
pelleted commercial rodent diet (Oriental Yeast, Tokyo,
Japan). The experimental protocol was approved by the
Kagawa University Animal Study Committee.
A powder form of [1-hydroxy-3-(methylpentylamino)-
propylidene] bisphosphonic acid sodium salt (ibandronate;
F. Hoffmann-La Roche, Basel, Switzerland) was dissolved
in isotonic saline and the pH adjusted to 7.4. The solution
was stored in a normal refrigerator (4C). The doses are
expressed as micrograms per kilogram of free acid equiv-
alents of ibandronate. For all animals, the volume admin-
istered was 1 mL/kg, injected subcutaneously.
Experimental Design
Animals were randomly allocated into four groups based on
body weight: control (CNT, saline vehicle), DAY (daily
ibandronate5 lg/kg,5 days/week),I-3(ibandronate75 lg/kg
every 3 weeks), and I-6 (ibandronate 150 lg/kg every
6 weeks). At the initiation of treatment, femoral osteotomy
and ﬁxation were performed in the same manner as previ-
ously reported [18–21, 23, 24]. Brieﬂy, a transverse osteot-
omy was made at the midshaft of the left femur, the
fragments were contacted and stabilized, then the intra-
medullary was ﬁxed using a stainless steel wire (diameter
1.5 mm). The wire was cut on the surface of the interc-
ondylar groove to avoid restriction of motion of the knee
joint. ‘‘Osteotomy,’’ therefore, describes the surgical pro-
cedureand‘‘fracture’’denotesthebreakintheboneresulting
from osteotomy. Unrestricted activity was allowed after
recovery from anesthesia. Body weights were measured
weekly, and treatment dosages were adjusted accordingly.
Dosing was initiated immediately after osteotomy and con-
tinued at 5 days per week until death; saline vehicle was
given daily except for scheduled dosing of ibandronate to
animals in the I-3 and I-6 groups. Total doses of ibandronate
were equivalent in the three treatment groups. In order to
analyze bone formation, double labeling was performed for
all surviving animals by subcutaneous administration of
calcein(6 mg/kg;Wako,Osaka,Japan)7and2 dayspriorto
necropsy. Rats were killed by exsanguination from the
abdominal artery under general anesthesia at 6 or 18 weeks
afterthesurgery,attheendoftheintermittentdosinginterval
and before the next scheduled dose.
Evaluations
X-ray Photography
Right femora were excised and dissected free of soft tis-
sues, and intramedullary wires were extracted. Antero-
posteriorly, soft X-ray radiographs of the femora were
taken (20 kV, 100 lA, 60 s; lFX-1000; Fujiﬁlm, Tokyo,
Japan). The presence of fracture lines was assessed by three
orthopedic surgeons and considered ‘‘healed’’ if agreed on
by at least two of the surgeons.
All femora were randomly divided into two evaluation
groups. The ﬁrst group was undecalciﬁed, assigned for
peripheral quantitative and computed tomography (pQCT),
mechanical testing, contact micrograph, and histmorpho-
metrical measurements. The other group was decalciﬁed
and assigned for tartrate-resistant acid phosphatase (TRAP)
staining.
pQCT Analysis
Specimens were frozen at -80C and wrapped in gauze
soaked in isotonic saline until pQCT measurement. After
thawing at room temperature, the right femora were scan-
ned by pQCT (Norland/Stratec XCT Research SA; Stratec
Medizintechnic, Pforzheim, Germany). The bones were
placed horizontally inside a glass tube and scanned using a
voxel size 0.12 mm. The scan line was adjusted using the
scout view of the pQCT system. For analysis, a constant
threshold of 464 mg/cm
3 was used to separate the bone area
from the marrow. The volumetric total BMD (mg/cm
3)o f
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moment of inertia (CSMI, mm
4) was also calculated;
however, the threshold value (464 mg/cm
3) was applied to
enhance the accuracy of the CSMI calculated through
pQCT in this fracture model.
Mechanical Testing
After pQCT scanning, the femora were tested for mechanical
properties by a three-point bending method using a materials
testing machine (MZ500S; Maruto, Tokyo, Japan). A femur
was placed on two lower support bars (15 mm apart) with the
anterior surface facing upward. The fracture plane was cen-
tered at the loading point, and load was applied at a rate of
2.5 mm/min until breakage. From the load versus displace-
ment curve, the structural mechanical properties of the
osteotomized bone were determined as ultimate load (maxi-
mumforcethatthespecimensustained),stiffness (theslope of
the linear portion of the load vs. deformation curve before
failure), and work to failure (the area under the load vs.
deformation curve before failure). As previously described,
because these structural parameters depend on te size and
geometryofthetestingspecimens,theywerenormalizedusing
CSMI to obtain intrinsic material properties such as ultimate
stress (MPa), elastic modulus (MPa), and toughness (MJ/m
3),
which are independent of cross-sectional size and shape [25].
Histologic Preparation and Contact Microradiograph
After mechanical testing, the proximal segments of the
fracture were repositioned, ﬁxed in 70% ethanol, stained in
Villanueva bone stain, dehydrated in increasing concentra-
tions ofethanol,defatted inxylene, andembedded in methyl
methacrylate. Two 200-lm-thick cross sections were cut
using a diamond microtome saw (SP1600; Leica, Nussloch,
Germany) in an area within 500 lm from the original frac-
ture line and then ground to 100 lm thickness for digital
contact microradiographs (100 kV, 2 mA, 5 min; lFX-
1000; Fujiﬁlm) and 30 lm thickness for histomorphometry.
The remaining distal segments of the fracture were
ﬁxed in 10% cold neutral buffered formalin for 3 days and
then decalciﬁed in 10% ethylenediaminetetraacetic acid
(EDTA) at 4C for 4 weeks. Specimens were embedded in
parafﬁn, and 5-lm-thick cross sections were cut in an area
within 500 lm from the original fracture line. The section
was stained with TRAP using a leukocyte acid phosphatase
kit (Sigma, St. Louis, MO).
Histomorphometry
Histomorphometric analyses were performed with a
semiautomated digitizing image analyzer. The system com-
prisedalightorepiﬂuorescentmicroscopeandadigitizingpad
coupled with computer and histomorphometric software
(System Supply, Nagano, Japan). Polarized light was applied
to distinguish lamellar bone from woven bone. Total area
(T.Ar, mm
2) and callus area (Cl.Ar, mm
2) were measured at
910magniﬁcation,andpercentcallusarea(%Cl.Ar = Cl.Ar/
T.Ar * 100, %) was calculated. Further measurements were
made at 9100 magniﬁcation in four standardized quarters in
the anterior, posterior, medial, and lateral aspects as previ-
ously described [18]. Callus surface (Cl.S), single-labeled
surface(sLS),double-labeledsurface(dLS),andinterlabeling
width (Ir.L.Wi) were measured at the callus. Diffuse labeled
areawasexcludedfromthemeasurement.Mineralapposition
rate (MAR, lm/day), mineralizing surface (MS/Cl.S, %),
boneformationrate(BFR/Cl.S,%),andpercentlamellararea
(Lamellar/Cl.Ar) were calculated. Osteoclast measurements
were also performed at 9 100 magniﬁcation in the four
standardized quarters. The number of osteoclasts (N.Oc) was
determined and N.Oc/Cl.S (#/mm) calculated.
Statistical Analysis
Statistical computation of data was performed using the
statistical package Stat View 5.0 (SAS Institute, Cary, NC).
Differences among treatment groups were tested by one-
way analysis of variance (ANOVA). If a signiﬁcant dif-
ference was obtained, differences between the means of the
two groups were tested by Fisher’s protected least signiﬁ-
cant difference. P\0.05 was considered signiﬁcant.
Results
No differences were found in body weight among all
groups during the study period. The animals resumed
normal activity within a few days after surgery. From 160
animals at the beginning of the study, 11 were excluded
because of technical failure, postsurgical infection, or
death. Finally, 74 and 75 animals were evaluated and
analyzed at 6 and 18 weeks after surgery, respectively.
Radiologic Findings
Soft X-ray images (Fig. 1) showed that although fracture
lines had disappeared in almost 90% of the CNT group,
they were still present in more than half of the ibandronate-
treated animals at 6 weeks postosteotomy. At 18 weeks, all
fracture lines had disappeared in the CNT and I-6 groups;
however, approximately 10% of fracture lines remained in
the DAY and I-3 groups (Table 1).
Contact microradiographs (Fig. 2) at 6 and 18 weeks
after osteotomy revealed that the ibandronate treatment
groups had visually larger calluses than CNT; however, at
18 weeks the callus sizes of all groups appeared to be
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apparent, which was still porous in the DAY group.
pQCT Analysis
Bone mineral content (BMC) around the fracture site was
signiﬁcantly increased with ibandronate treatment vs. CNT
(P\0.05), and the increase was dependent on a shortened
ibandronate administration interval at both 6 and 18 weeks
after osteotomy (Table 2). However, no signiﬁcant differ-
ences were found between groups in volumetric BMD at 6
or 18 weeks. CSMI, a geometrical parameter of cross-
sectional shape, was also signiﬁcantly increased by
ibandronate versus CNT (P\0.05) (Table 2); however,
these CSMI increases tended toward a numerical reduction
with increasing treatment interval.
Mechanical Testing
At 6 weeks after osteotomy, stiffness was signiﬁcantly
higher in DAY than in CNT or I-3 femora (P\0.05).
Fig. 1 Soft X-ray photography of fractured femora. Fracture lines
had disappeared in almost 90% of the control group but were still
present in more than half of ibandronate-treated groups at 6 weeks
postfracture. At 18 weeks all fracture lines had disappeared in control
and I-6 groups; however, about 10% of fracture lines remained in the
DAY and I-3 groups
Table 1 Visible fracture lines
in control (CNT), DAY, I-3, and
I-6 groups
a Data in parentheses are
number of animals with visible
fracture line/total number of
animals in treatment group
Visible fracture lines (%)
a CNT DAY I-3 I-6
6 weeks after osteotomy 12.5
(n = 2/16)
57.9
(n = 11/19)
78.9
(n = 15/19)
50.0
(n = 10/20)
18 weeks after osteotomy 0
(n = 0/20)
17.6
(n = 3/17)
11.1
(n = 2/18)
0
(n = 0/20)
Fig. 2 Contact
microradiographs of cross-
sectional specimens at the
fracture plane. At 6 and
18 weeks after osteotomy
ibandronate treatment groups
had visually larger calluses than
CNT. At 18 weeks the callus
sizes of all groups appeared to
be smaller than at 6 weeks and
new cortical shell was apparent,
which was still porous in the
DAY group
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signiﬁcantly, higher in DAY than in CNT femora; no sig-
niﬁcant differences between the ibandronate dosing groups
were seen. When these data were normalized using the
CSMI,toexcludetheeffectofincreasedcallusvolumedueto
the treatment, the intrinsic material properties, such as ulti-
matestressandelasticmodulus,weresigniﬁcantlydecreased
by ibandronate treatment (P\0.05 vs. CNT). Ultimate
stress was signiﬁcantly reduced in I-3 versus 1-6 femora
(P\0.05), but no other signiﬁcant differences were noted
between the dosing groups. Intrinsic material properties
became closer to those of the CNT group in response to an
increased interval of ibandronate administration (Table 3).
Among the structural mechanical properties at 18 weeks
after osteotomy, only ultimate load in DAY femora was
signiﬁcantly higher than in CNT (P\0.05). Intrinsic
material properties were signiﬁcantly decreased by ibandr-
onate treatment (P\0.05 vs. CNT); the only signiﬁcant
difference between ibandronate dosing groups was in
elastic modulus in DAY vs. I-6 femora (P\0.05).
Increasing the interval of ibandronate administration less-
ened the decreases in ultimate stress and elastic modulus.
Table 2 pQCT analysis
CNT DAY I-3 I-6
6 weeks after osteotomy (n = 16) (n = 19) (n = 18) (n = 20)
BMC (mg) 12.89 ± 0.89 24.43 ± 1.70
C, I-6 21.85 ± 1.31
C, I-6 16.67 ± 0.80
C
BMD (mg/cm
3) 973.52 ± 15.12 1,012.59 ± 19.83 981.77 ± 14.48 1,001.19 ± 23.70
CSMI (mm
4) 24.13 ± 3.78 63.36 ± 9.49
C, I-6 55.62 ± 7.08
C, I-6 35.04 ± 3.55
18 weeks after osteotomy (n = 20) (n = 17) (n = 18) (n = 20)
BMC (mg) 12.50 ± 0.76 27.35 ± 1.94
C, I-3, I-6 21.33 ± 1.35
C 20.47 ± 1.10
C
BMD (mg/cm
3) 1,217 ± 12.17 1,204.16 ± 13.12 1,211.33 ± 9.06 1,224.72 ± 13.32
CSMI (mm
4) 14.25 ± 1.51 44.92 ± 6.22
C, I-3, I-6 29.10 ± 3.60
C 26.82 ± 2.46
C
Data are mean values ± standard error, with signiﬁcant differences from CNT, DAY, I-3, and I-6 indicated by C, D, I-3, and I-6, respectively
(P\0.05, Fisher’s projected least signiﬁcant difference)
Table 3 Biomechanical properties of fractured femur
CNT DAY I-3 I-6
6 weeks after osteotomy (n = 16) (n = 19) (n = 18) (n = 20)
Structural mechanical properties
Ultimate load (N) 83.7 ± 8.4 129.1 ± 27.9 75.6 ± 22.8 91.04 ± 8.76
Stiffness (N/mm) 7,919 ± 368 10,446 ± 937
C, I-3 8,028 ± 936 8,302 ± 707
Work to failure (N-mm) 74,113 ± 16,199 104,456 ± 28,619 65,334 ± 14,525 74,587 ± 11,407
Intrinsic material properties
Ultimate stress (MPa) 36.5 ± 2.9 24.5 ± 4.6
C 15.1 ± 3.8
C, I-6 30.9 ± 4.0
Elastic modulus (MPa) 27,913 ± 3,925 12,732 ± 2,102
C 10,750 ± 1,217
C 17,386 ± 1,717
C
Toughness (MJ/m
3) 4,255 ± 756 3,204 ± 674 2,391 ± 660 4,287 ± 946
18 weeks after osteotomy (n = 20) (n = 17) (n = 18) (n = 20)
Structural mechanical properties
Ultimate load (N) 140.3 ± 10.9 224.0 ± 27.4
C 184.8 ± 18.6 171.9 ± 10.3
Stiffness (N/mm) 12,134 ± 786 13,347 ± 788 12,038 ± 737 13,219 ± 818
Work to failure (N-mm) 120,539 ± 18,359 153,667 ± 29,530 123,590 ± 24,171 106,071 ± 14,529
Intrinsic material properties
Ultimate stress (MPa) 79.7 ± 4.0 53.3 ± 3.9
C 60.9 ± 4.6
C 60.0 ± 4.5
C
Elastic modulus (MPa) 62,593 ± 3,825 26,343 ± 3,547
C, I-6 31,989 ± 2,690
C 37,541 ± 4,707
C
Toughness (MJ/m
3) 7,581 ± 1,001 4,868 ± 666
C 5,260 ± 1,019 4,730 ± 714
C
Data are mean values ± standard error, with signiﬁcant differences from CNT, DAY, I-3, and I-6 indicated by C, D, I-3, and I-6, respectively
(P\0.05, Fisher’s projected least signiﬁcant difference)
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After osteotomy, observations in the CNT group at the
6- and 18-week time points indicated that T.Ar and T.Cl.Ar
decreased as a result of shrinkage of the fracture callus and
bone formation parameters decreased. In addition, Lamel-
lar/Cl.Ar was 63% at 6 weeks in the CNT group, reaching
100% at 18 weeks after osteotomy in this group (Table 4;
Fig. 3).
Following ibandronate treatment, bigger callus forma-
tion and delayed callus remodeling were observed in an
apparent interval-dependent manner. T.Ar and T.Cl.Ar
were signiﬁcantly higher in DAY than in CNT femora at
6 weeks postosteotomy (P\0.05), with nonsigniﬁcant
numerical decreases in T.Ar and T.Cl.Ar from DAY
toward CNT levels in the I-3 and I-6 groups (Table 4).
DAY femora showed signiﬁcantly larger T.Ar than all
other treatment groups at 18 weeks after osteotomy
(P\0.05). At 18 weeks, T.Ar and T.Cl.Ar were numeri-
cally reduced in all groups compared with the 6-week time
point. T.Ar and T.Cl.Ar for I-3 and I-6 were between DAY
and CNT values, although all groups were signiﬁcantly
different from CNT. These data suggest less shrinkage of
the fracture callus, especially in the DAY group compared
with the CNT group.
Lamellar/Cl.Ar was signiﬁcantly reduced in ibandronate-
treated groups compared with CNT, and the extent of the
reduction lessened as the ibandronate administration inter-
val was shortened (Table 4). Similarly, bone remodeling
parameters, such as the ﬂuorochrome label-based bone for-
mation parameter or the static bone resorption parameter,
were signiﬁcantly decreased by ibandronate treatment vs.
CNT(P\0.05);andthesedecreasesbecamemoreapparent
in response to shortening of the administration interval.
Interval-dependent numerical changes were observed for
MAR, BFR/Cl.S, MS/Cl.S, and N.Oc/Cl.S, which are all
Table 4 Bone histomorphometry in fracture callus
CNT DAY I-3 I-6
6 weeks after osteotomy (n = 16) (n = 19) (n = 18) (n = 20)
T.Ar (mm
2) 22.78 ± 1.72 29.67 ± 2.31
C 29.89 ± 1.90
C 26.40 ± 2.21
T.Cl. Ar (mm
2) 15.63 ± 1.38 21.39 ± 2.26
C 19.62 ± 2.19 18.75 ± 1.54
Lamellar/callus (%) 62.6 ± 7.2 31.3 ± 8.8
C, I-3, I-6 43.0 ± 11.1
C, I-6 52.9 ± 4.5
C
MAR (lm/day) 3.17 ± 0.28 0.39 ± 0.26
C, I-3, I-6 2.15 ± 0.45
C 2.38 ± 0.12
BFR/Cl.S (mm
3/mm
2/year) 0.302 ± 0.040 0.002 ± 0.001
C, I-6 0.050 ± 0.018
C 0.093 ± 0.011
C
MS/Cl.S (%) 25.63 ± 2.04 1.12 ± 0.22
C, I-6 5.23 ± 1.81
C 9.58 ± 1.67
C
N.Oc/Cl.S (#/mm) 4.26 ± 1.10 0.75 ± 0.31
C 0.71 ± 0.33
C 1.38 ± 0.34
C
18 weeks after osteotomy (n = 20) (n = 17) (n = 18) (n = 20)
T.Ar (mm
2) 15.62 ± 0.85 24.59 ± 1.76
C, I-3, I-6 20.62 ± 1.12
C 20.01 ± 0.87
C
T.Cl.Ar (mm
2) 9.69 ± 0.77 16.63 ± 1.74
C 13.89 ± 1.21
C 13.33 ± 0.60
C
Lamellar/callus (%) 100 67.8 ± 15.2
C, I-3, I-6 86.2 ± 11.0
C, I-6 95.9 ± 4.1
MAR (lm/day) 2.81 ± 0.25 0.25 ± 0.18
C, I-3, I-6 0.94 ± 0.49
C 2.32 ± 0.39
BFR/Cl.S (mm
3/mm
2/year) 0.17 ± 0.034 0.008 ± 0.007
C, I-6 0.010 ± 0.005
C 0.048 ± 0.010
C
MS/Cl.S (%) 15.19 ± 3.13 0.86 ± 0.16
C, I-6 2.17 ± 0.46
C 5.71 ± 1.11
C
N.Oc/Cl.S (#/mm) 4.10 ± 1.07 0.40 ± 0.07
C, I-6 0.94 ± 0.10
C 2.10 ± 0.32
C
Data are mean values ± standard error, with signiﬁcant differences from CNT, DAY, I-3, and I-6 indicated by C, D, I-3, and I-6, respectively
(P\0.05, Fisher’s projected least signiﬁcant difference)
Fig. 3 Photomicrographs of the callus at 6 and 18 weeks after
osteotomy, under epiﬂuorescence and polarized light. At 6 weeks The
labeled surface and lamellar bone in the callus were less in all
treatment groups than CNT. At 18 weeks lamellar bone formation
was active in the CNT and I-6 groups, while less lamellar and more
woven bone were observed in the DAY group than in any other
groups
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changes were not signiﬁcant between the ibandronate treat-
ment groups (Table 4).
Discussion
Dosing convenience is a key element in the effective
management of any chronic disease and is particularly
important in the long-term management of osteoporosis.
Less frequent dosing with any medication may enhance
compliance, thereby maximizing the effectiveness of
therapy. Bisphosphonate therapy effectively reduces the
risk of osteoporotic fractures [26–28]; however, fracture
protection depends critically on adherence and persistence.
Bisphosphonate treatments with extended dosing intervals
are more convenient for patients than daily dosing;
patients’ satisfaction with treatment is improved, as is their
likelihood of remaining on therapy, ultimately improving
the clinical beneﬁts of treatment [29, 30]. These extended
dosing intervals for bisphosphonates are based on the ‘‘total
dose concept’’ that bone protection by bisphosphonates is a
function of the total effective dose of the compound
regardless of the regimen used, whether continuous or
cyclical intermittent [10]. However, the total dose concept
may not be applicable universally but depends on the
properties of each individual drug. For example, weekly
risedronate and alendronate are administered at the same
cumulative dose as daily administration (equivalent to
seven times the standard daily dose) [11–14], whereas
monthly ibandronate (150 mg) is twice the cumulative
daily dose. Notably, however, a lower dose of monthly
ibandronate (100 mg), which is closer to the daily cumu-
lative dose, provided the same beneﬁts as daily dosing in
the MOBILE study [17]. While this concept has been
proven in both osteoporotic animal models and human
osteoporosis, the effects of the dosing interval duration for
bisphosphonates on the fracture healing process have never
been tested.
The histomorphometric ﬁndings of the present study
showed inhibition of both bone resorption and formation
and less lamellar bone in the callus area in ibandronate-
treated groups, indicating delayed callus remodeling into
lamellar bone. Larger callus volume and cross-sectional
area (moment of inertia) in ibandronate-treated groups
appeared to be a compensation mechanism for the delay in
remodeling woven bone into lamellar bone, which is
structurally and mechanically superior to woven bone.
These observations are consistent with our previous studies
using other bisphosphonates, incadronate and alendronate
[18–21].
The primary aim of this study was to examine the effect
of extended dosing intervals for ibandronate on the healing
process following osteotomy in the femoral fracture model
in rats. Our results demonstrated that extension of the
dosing interval reduced suppression of callus remodeling of
woven bone into lamellar bone, suggesting that extended
bisphosphonate dosing intervals may bring the healing
process for ‘‘fractures’’ following osteotomy closer to what
is natural. The total dose concept may not therefore be
applicable for this healing process in rats. There are several
explanations for this phenomenon. Firstly, although bis-
phosphonates bind to bone surfaces because of a high
afﬁnity to hydroxyapatite, the amount of deposited bis-
phosphonate may be limited in a single dosing regimen.
Thus, the total amount of compound within the bone may
be less in the intermittent treatment groups than in the daily
treatment group. Secondly, bisphosphonates have different
bone binding afﬁnities, which, in addition to resorption
rate, most likely determine the rate of release from bone.
Ibandronate has a lower binding afﬁnity than zoledronate
and alendronate but a greater bone binding afﬁnity than
risedronate [31, 32]. Thus, in the intermittent treatment
groups, a substantial amount of deposited ibandronate may
have been desorbed from the bone during the dosing
interval, resulting in less suppression of callus remodeling
in the intermittent ibandronate treatment groups vs. the
DAY group. Additionally, the greater the dosing interval,
the longer the recovery time for bone remodeling, as evi-
denced by the histomorphometric data for the DAY vs. the
intermittent ibandronate treatment groups. These ﬁndings
are supported by our previous fracture study using in-
cadronate, in which bisphosphonate concentrations in bone
were measured in the fracture callus in comparison with
contralateral intact bone. We found a time-dependent
decrease in incadronate concentration in the fracture callus
after its withdrawal, whereas it remained unchanged in
contralateral intact bone, indicating that the release of in-
cadronate from bone depends on the rate of local bone
turnover [18–20].
The current study could not establish whether the dif-
ferent intermittent ibandronate dosing schedules, adminis-
tered to the same total cumulative dose, showed comparable
antifracture efﬁcacy. Some caution should be exercised
when interpreting the clinical relevance of these results in
terms of treatments for osteoporosis. Young rats were used
(8–9 weeks old at the time of treatment initiation), which is
consistent with previous studies in the rat fracture model
[18–21, 23, 24, 33]; however, in terms of clinical relevance,
this is a weakness of the study as the fracture healing pro-
cess in these animals will differ from that of patients with
osteoporosis. In addition, the total dose of ibandronate used
in the DAY group was higher than the clinical daily dose for
osteoporosis treatment; however, the doses used were
chosen to inhibit the high metabolic turnover in this rat
model and to produce sufﬁcient callus to detect differences
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tent groups. In addition, how the treatment intervals in this
rat study compare with those used in patients with osteo-
porosis is unclear. If the histomorphometric remodeling
period is considered, a dosing interval of 3–6 weeks in the
rat is equivalent to approximately 3–6 months in humans,
assuming that the remodeling period in the rat is about
30 days. Alternatively, based on the life span of the animal
(approximately 2 years for rats), 3–6 weeks in rats is
equivalent to 2–4 years in humans, which would suggest
that the dosing intervals used in this study are longer than
those in the treatment of osteoporosis in humans.
Conclusion
Based on histomorphometric and biomechanical evalua-
tions of osteotomized femora in rats treated with the same
total doses of ibandronate in three different dosing intervals
(daily, every 3 weeks, and every 6 weeks), we conclude the
following: (1) ibandronate treatment induced formation of
large fracture calluses but delayed woven bone remodeling
into lamellar bone and reduced intrinsic material properties,
(2) shortening the dosing interval of ibandronate treatment
without changing the total dose enhanced suppression of
callus remodeling and appeared to delay the healing process
after osteotomy, and (3) extending the dosing interval of
intermittent ibandronate treatment appeared to reduce the
suppression of callusremodeling caused by ibandronate that
would have delayed healing after osteotomy.
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